Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels.

ICD implantation boosts survival after cardiac arrests with reversible causes

Current clinical guidelines recommend implantable cardioverter-defibrillators (ICDs) in survivors of sudden cardiac arrest (SCA), except when the cause of the SCA is deemed reversible. But a new study in Circulation: Arrhythmia and Electrophysiology demonstrates that many of these patients gain a survival benefit from ICDs as well.